Van Gompel Jamie J, Link Michael J, Sheehan Jason P, Xu Zhiyuan, Mathieu David, Kano Hideyuki, Lunsford L Dade
Departments of Neurosurgery, Mayo Clinic, Rochester, Minnesota, United States.
Department of Neurosurgery, University of Virginia Health System, Charlottesville, Virginia, United States.
J Neurol Surg B Skull Base. 2014 Dec;75(6):409-14. doi: 10.1055/s-0034-1378151. Epub 2014 Jun 4.
Objective Esthesioneuroblastoma (ENB) is a rare malignant neuroendocrine neoplasm that is prone to both local and metastatic recurrence. Local recurrence may often be treated with repeat resection. However, stereotactic radiosurgery (SRS) offers a noninvasive option. Design Prospective database review. Participants Gamma knife prospective databases were queried at all institutions within the North American Gamma Knife Consortium, 16 at the time of this report. All patients who had undergone SRS for ENB were included. Main Outcome Measure Response of recurrent ENB to SRS. Results A total of 31 locally recurrent tumors in 13 patients were treated with SRS. The median age was 49 years (range: 19-79 years). At a median follow-up of 36 months (range: 1-100 months), 13 (48%) treated tumors were smaller, 11 (41%) were stable, and 3 (11%) showed continued growth following SRS. Univariate analysis did not find any significant factor relating to failure of treatment. Notably, no treatment-related complications (0%) were observed in this cohort. Conclusion SRS appears to provide a safe and effective option for treatment of recurrent intracranial ENB. Overall, 89% of treated tumors were controlled in this multi-institutional study.
嗅神经母细胞瘤（ENB）是一种罕见的恶性神经内分泌肿瘤，易于局部复发和转移复发。局部复发通常可通过再次切除进行治疗。然而，立体定向放射外科（SRS）提供了一种非侵入性选择。
前瞻性数据库回顾。
查询了北美伽玛刀协会所有机构的伽玛刀前瞻性数据库，本报告发布时共有16个机构。纳入了所有接受SRS治疗ENB的患者。
复发性ENB对SRS的反应。
13例患者的31个局部复发性肿瘤接受了SRS治疗。中位年龄为49岁（范围：19 - 79岁）。中位随访36个月（范围：1 - 100个月），13个（48%）接受治疗的肿瘤缩小，11个（41%）稳定，3个（11%）在SRS后持续生长。单因素分析未发现与治疗失败相关的任何显著因素。值得注意的是，该队列中未观察到任何与治疗相关的并发症（0%）。
SRS似乎为复发性颅内ENB的治疗提供了一种安全有效的选择。总体而言，在这项多机构研究中，89%的接受治疗的肿瘤得到了控制。
